<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125524</url>
  </required_header>
  <id_info>
    <org_study_id>265479</org_study_id>
    <nct_id>NCT04125524</nct_id>
  </id_info>
  <brief_title>Terahertz Metamaterials for Tumour Marker Concentration Identification</brief_title>
  <official_title>Terahertz Metamaterials for Tumour Marker Concentration Identification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durham University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>County Durham and Darlington NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Durham University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research the investigators plan to undertake involves the use of a metamaterial at&#xD;
      terahertz frequencies. Serum samples will be tested using the metamaterial to determine if&#xD;
      this method can be used to measure the concentration of tumour markers present in the sample.&#xD;
      Patients who have been tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP will&#xD;
      be used for both the positive and negative samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research the investigators plan to undertake involves the use of a paper substrate with a&#xD;
      gold metamaterial on top or a plastic substrate with gold metamaterial on top in physical&#xD;
      contact with paper. The metamaterial has an absorption peak within the terahertz frequency&#xD;
      range to be investigated (0.75 - 1.1THz). The serum samples will be soaked into the paper&#xD;
      fibres which will shift the absorption peak within the terahertz frequency range dependent on&#xD;
      the concentration of tumour markers present in the sample. The serum samples will be surplus&#xD;
      from samples tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP at the Durham&#xD;
      and Darlington NHS Fondation Trust. The samples will be anonymised with the exception of&#xD;
      which tumour marker they were tested for and the level measured.&#xD;
&#xD;
      There will be two stages to this research project the initial stage requires 15 samples per&#xD;
      proposed marker including 15 samples (across all markers) for negative results. This will be&#xD;
      used to identify suitable markers to consider for the second stage. Where 50 to 90 samples of&#xD;
      each qualifying marker will be tested dependent on the number required for statistical&#xD;
      confidence in stage two with 10 to 18 negative samples required for each qualifying marker,&#xD;
      again dependent on the statistical requirements for each marker.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of detection for any marker</measure>
    <time_frame>18 months</time_frame>
    <description>Any correlation showing a difference between samples with marker concentrations above and below the standard threshold values used for tests within the NHS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantifying the quality of detection per marker</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage of detectable samples for each specific marker which showed any evidence of detection in outcome 1.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Malignant Tumour</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Terahertz metamaterials</intervention_name>
    <description>A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Surplus serum samples remaining after hospital tests.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        County Durham and Darlington NHS Foundation Trust&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient recommended by their health professional to be tested for any of the&#xD;
             tumour markers being studied at County Durham and Darlington NHS Foundation Trust for&#xD;
             any reason.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known bloodborne pathogens.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Engineering Durham University</name>
      <address>
        <city>Durham</city>
        <zip>DH1 3LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumour markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Outcomes will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

